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Current published protocols for targeted differentiation of human stem cells toward
pancreatic β-cells fail to deliver sufficiently mature cells with functional properties
comparable to human islet β-cells. We aimed to assess whether Wnt-modulation could
promote the final protocol stages of β-cell maturation, building our hypothesis on
our previous findings of Wnt activation in immature hiPSC-derived stage 7 (S7) cells
compared to adult human islets and with recent data reporting a link between Wnt/PCP
and in vitro β-cell maturation. In this study, we stimulated canonical and non-canonical
Wnt signaling in hiPSC-derived S7 cells using syntetic proteins including WNT3A, WNT4,
WNT5A and WNT5B, and we inhibited endogenous Wnt signaling with the Tankyrase
inhibitor G007-LK (TKi). Whereas neither canonical nor non-canonical Wnt stimulation
alone was able to mature hiPSC-derived S7 cells, WNT-inhibition with TKi increased the
fraction of monohormonal cells and global proteomics of TKi-treated S7 cells showed
a proteomic signature more similar to adult human islets, suggesting that inhibition of
endogenous Wnt contributes toward final β-cell maturation.
Keywords: human induced pluripotent stem cell, β-like cells, Wnt signaling pathway, tankyrase inhibition, in vitro
maturation, proteomics, TMT11-plex, adult human islets
INTRODUCTION
Despite ongoing progress, it is at present still not possible to generate mature insulin-producing
cells from human induced pluripotent stem cells (hiPSCs) that capture all aspects of endogenous
β-cell in vitro. Cells generated with current published multi-step protocols (1–3) show elevated
basal insulin secretion levels and insufficient glucose-responsiveness (4, 5), and are thus considered
functionally immature (4). Additionally, in vitro differentiation leads to the generation of highly
heterogeneous cell populations, largely composed of bi-hormonal (insulin+/glucagon+) cells
alongside diverse categories of progenitor cells (6). It remains unclear to date, which signaling
pathways will promote the last steps of β-cell differentiation and functional maturation, as well
as whether these mechanisms can be specifically activated in vitro.
A candidate pathway contributing to β-cell maturation was recently suggested by Bader et al.
(7), confirming a link between active non-canonical Wnt/planar cell polarity (PCP) signaling and
in vitro β-cell maturation, as assessed in dispersed and re-aggregated post natal day 5 (P5) islet
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cells, pseudo-islets of Min6 insulinoma cells as well as in the
human β-cell line (EndoC-β H1). The Wnt signaling pathways
are a group of highly conserved pathways that regulate key
aspects of cell fate decisions, migration, polarity, patterning and
organogenesis during embryonic development (8–12). Previous
studies have focused on the role of Wnt signaling in β-cell
function (7, 13). Wnt signaling is highly conserved and serves
as a stem cell niche signal in many contexts, as β-catenin is
required to maintain an undifferentiated cell state (14, 15). In the
pancreas, Wnt signaling is essential for pancreas development,
islet function, and for the production and secretion of insulin
in β-cells (16). Stage-specific signaling through Wnt regulates
patterning and pancreas specification of human pluripotent stem
cells, and canonical Wnt signaling has been found to induce
a posterior endoderm fate and to enhance the development of
pancreatic linage cells (17).
In our previous study comparing the proteome of S7 cells
against the proteome of adult human pancreatic islets, we
detected strong canonical and non-canonical Wnt pathway
activation in S7 cells as compared to islets (18), suggesting that
inhibition of the endogenous Wnt signaling could potentially
promote the differentiation of S7 cells toward a more mature
phenotype. Combined with recent data reporting that Wnt/PCP
can trigger in vitro β-cell maturation (7), induced by WNT4
and WNT5A treatment, we hypothesized that Wnt modulation
of S7 cells may affect their in vitro maturation potential.
In this study, we expanded the selection of Wnt ligands to
include WNT3A, WNT4, WNT5A, WNT5B, and WNT5A&5B
combined. Moreover, to further test our hypothesis that
inhibition of endogenous Wnt signaling drives S7 cells out of
a progenitor state toward a more mature phenotype, we used
the small molecule Tankyrase inhibitor G007-LK (TKi) to block
endogenous Wnt signaling in S7 cell cultures.
MATERIALS AND METHODS
Cell Source
In this study, we used human induced pluripotent cell
(hiPSC) lines from healthy subjects obtained from three
independent sources. The commercial control hiPSCs
(ND41866) reprogrammed from fibroblasts using retroviral
vectors (OCT4, SOX2, KLF4, CMYC) were purchased from
Coriell Institute for Medical Research (Camden, NJ, USA).
One line of normal healthy fibroblasts was reprogrammed
by Sendai virus by Cellartis (Tekara Bio), and in parallel an
additional fibroblast line from a normal healthy donor were
episomal reprogrammed (in house) with plasmids (hUL, hSK,
hOCT4/shp53), [27077 (pCXLE-hOCT3/4-shp53-F), 27078
(pCXLE-hSK) and 27080 (pCXLE-hUL)] all from Addgene.
Human islets (n = 6 donors) were isolated as described
previously (19) from pancreata obtained from three female and
three male brain-dead deceased donors after informed consent
from relatives for organ donation and for use in research at
the islet isolation facility of Oslo University Hospital, Oslo,
Norway. All hiPS cell lines were subjected to Stage-specific
embryonic antigen 4 (SSEA4) enrichment (SSEA4 microbeads,
MACS Miltenyi Biotec) before proceeding to differentiation.
All iPSCs cell lines were confirmed to have normal karyotype,
and to be mycoplasma free using a MycoAlert Mycoplasm
Detection Kit (LT07-418, Lonza). All experiments with hiPSCs
were approved by the Regional Committee of Medical and
Health Research Ethics: hiPSCs (REK 2010/2295) and islets (REK
2011/426), and all methods were performed in accordance with
the Helsinki Declaration.
In vitro Differentiation Protocol
Three hiPSC lines were differentiated according to a seven-stage
differentiation protocol (1) on Matrigel-coated plates for the
duration of the whole differentiation protocol, without transfer
to an air-liquid interface as we have reported previously (18).
The cells were grown in S7 media for 7 days (S7d7 cells), and
one well from each cell line was cultured for seven additional
days in S7 media (S7d14 cells). hiPSC-derived cells were in
parallel harvested for downstream immunofluorescence staining
on coverslips from the samewell as was harvested for quantitative
proteomics analysis, at the end of S6d7, S7d7, and S7d14 days,
respectively. Cells were also harvested 48 h after Wnt-treatment.
Wnt Ligand Treatment of S7 Cells
S7 cells were in parallel stimulated with Wnt5A (645-WN,
R&D Systems) (400 ng/mL), Wnt5B (7347-WN, R&D
Systems) (400 ng/mL), a combination of Wnt5A/Wnt5B
(400 ng/mL/80 ng/mL), Wnt4 (6076-WN, R&D Systems)
(100 ng/mL), Wnt3A (5036-WN, R&D Systems) (200 ng/mL),
and the tankyrase inhibitor G007-LK (5 µmol/L), for 4 h and
kept 48 h in S7 differentiation media before harvest. Media was
changed every day.
Apoptosis Monitoring
For monitoring the apoptosis status of Wnt stimulated hiPSC-
derived cells, and to find the time window for stimulation before
induction of apoptosis, we used the Dead Cell Apoptosis kit
with Annexin V and Propidium Iodide (PI) (V13241, Thermo
Scientific). In brief, 1X annexin-binding buffer was prepared by
adding 1mL 5X annexin-binding buffer (Component C) to 4mL
MCDB131 basal medium. Working solution of PI (100µg/mL)
was prepared by diluting 5 µL of the 1 mg/mL PI stock solution
(Component B) in 45 µL 1X annexin-binding buffer. Before
changing media, each well was treated with 5 µL Alexa Fluor R©
488 annexin V (Component A) and 1 µL 100µg/mL PI working
solution and cells were incubated at RT for 15min. We removed
all liquid and wash cells with 1X annexin-binding buffer (twice)
and added the different WNT factors diluted in MCDB131 basal
medium. Cells were monitored under a fluorescent microscope
every 15min for 4 h.
Cell Viability
We used the NucleoCounter R© NC-200TM for assessment of cell
viability after Wnt-modulation using the vendors instructions.
Static Incubation Glucose-Stimulated
Insulin Secretion
Wnt treated and untreated S7 cells were rinsed twice with DPBS
and then twice with Krebs buffer (129mMNaCl, 5mMNaHCO3,
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4.8mM KCl, 2.5mM CaCl2, 1.2mM MgSO4, 1mM Na2HPO4,
1.2mM KH2PO4, 10mM HEPES, 0.1% BSA) in deionized water
and then sterile filtered. The cells were pre-incubated in Krebs
buffer spikedwith 1.67mMglucose (Krebs buffer low glucose) for
30min. Media was collected after 30min, centrifuged to remove
unwanted cells and supernatant was transferred to a new vial.
After low glucose incubation, the cells were incubated in Krebs
buffer spiked with 20mM glucose (Krebs buffer high glucose)
for 30min, and media was collected. Followed by incubation in
Krebs buffer spiked with 20mM glucose and 30mM KCl for
10min. All supernatants were frozen at−80◦C until insulin levels
were measured by ELISA (#10-1113-01; Mercodia).
Immunofluorescence Staining
Cells were cultured on glass coverslips and fixed in 2%
paraformaldehyde (PFA) for 15min. The immunofluorescence
protocol performed conformed to indications provided by the
supplier. The following primary antibodies were used: mouse
anti-β-catenin (1/500, ab22656, Abcam), rabbit anti-BMP4
(1/500, ab39973, Abcam), rabbit anti-ROR2 (1/50, ab92379,
Abcam), rabbit anti-c-JUN (1/500, ab31419, Abcam), mouse
anti-insulin (1/500, I2018, Sigma-Aldrich), guinea-pig anti-
porcine insulin (1/500, A056401-2, Dako), mouse anti-porcine
glucagon (1/500, G2654, Sigma-Aldrich), rat anti-somatostatin
(1/100, sc-47706, Santa Cruz), guinea-pig anti-PDX1 (1/500,
ab47308, Abcam), and rabbit anti-NKX6.1 (1/100, NBP1-
82553, Novus), rabbit anti-MAFA (1/200, ab98859, Abcam).
The following secondary antibodies were used: donkey anti-
rabbit A488, donkey anti-rabbit A546, goat anti-mouse A568,
chicken anti-rat A647, and goat anti-guinea-pig A647 (1/500,
Molecular Probes). The nuclei were stained with DAPI (D1306,
Molecular Probes). The samples were mounted in Prolong
Diamond Antifade Mountant Media (P36970, Life technologies)
and were analyzed with Leica TCS SP5 STED CW confocal
microscope. No specific feature of the original data was obscured,
eliminated or misrepresented.
Cell Counting
From one coverslip, 20 snapshots were taken from different
areas on the coverslip. From each snapshot all insulin+ and
all glucagon+ cells were counted. Overlay of insulin+ and
glucagon+ were used to count bi-hormonal cells.
Global Proteomics Analysis
Cell Lysis and Protein Digestion
S6, S7d7, S7d14 and Wnt-modulated cell cultures were washed
in DPBS and harvested with TrypLETM Select Enzyme (1X)
(12563011, Thermo Fisher Scientific), followed by centrifugation.
Islets and hiPSC-derived cells were lysed as described previously
(18). The protein concentration was determined using a BCA
protein assay kit. Dry aliquots containing an estimated amount
of 100 µg of proteins were further processed using Filter-Aided
Sample Preparation (20). The six islet samples were combined
and mixed to make a homogenous mixture, and 50 µg protein of
the mix were aliqvoted into six separate samples for downstream
TMT11-plex analysis.
Tandem Mass Tag (TMT) 11 Plex Labeling
TMT reagents were re-suspended in ACN. Desalted peptides
were re-suspended in 50 µL of 200mM EPPS pH 8.5, 15 µL
of ACN, and 5 µL of the TMT reagents were added to the
respective peptide samples, gently vortexed, and incubated for
1.5 h at RT. To prevent unwanted labeling, the reaction was
quenched by adding 5 µL of 5% hydroxylamine and incubated
for 15min at RT. Equal amounts of the TMT-labeled samples
were combined and concentrated to near dryness, followed by
desalting via C18 solid phase extraction and passage over a Pierce
detergent removal spin column (Thermo Fisher Scientific).
Off-Line Basic pH Reversed Phase Fractionation
The combined labeled peptide samples were pre-fractionated
by basic pH reversed phase HPLC as described previously
(21), using an Agilent (P/N 770995-902) 300Extend-C18, 5µm,
250 × 4.6mm id column, connected to an Agilent Technology
off-line LC-system. Solvent A was 5% ACN, 10mM NH4HCO3
pH8, and solvent B was 90% ACN, NH4HCO3 pH 8. The samples
were re-suspended in 500 µL solvent A and loaded onto the
column. Column flow was set to 0.8 mL/min and the gradient
length was 70min, as follows: from 0 to 35min solvent 50%
A/50% B, and from 35 to 50min 100% B, and from 50 to
70min 100% A. The labeled peptides were fractionated into 96
fractions, and further combined into a total of 12 fractions (22).
Each fraction was acidified with 1% formic acid, concentrated by
vacuum centrifugation to near dryness, and desalted by StageTip.
Each fraction was dissolved in 5% ACN/ 5% formic acid for
LC-MS/MS analysis.
LC-MS3 Analysis
From each of the 12 fractions, ∼3 µg was dissolved in 1%
aqueous formic acid (FA) prior to LC-MS/MS analysis on an
Orbitrap Fusion mass spectrometer (Thermo Fisher Scientific,
San Jose, CA) coupled to a Proxeon EASY-nLC 1000 liquid
chromatography (LC) pump (Thermo Fisher Scientific). Peptides
were fractionated on a 75-µm inner diameter microcapillary
column packed with ∼35 cm of Accucore resin (2.6µm, 150 Å,
Thermo Fisher Scientific, San Jose, CA). For each analysis, we
loaded∼1 µg onto the column.
Peptides were separated using a 2.5 h gradient of 2–25%
acetonitrile in 0.125% formic acid at a flow rate of ∼350
nL/min. Each analysis used the multi-notch MS3-based TMT
method (23) on an Orbitrap Fusion mass spectrometer, which
has been shown to reduce ion interference compared to MS2
quantification (21). The scan sequence began with an MS1
spectrum (Orbitrap analysis; resolution 120,000; mass range
400–1,400 m/z; automatic gain control (AGC) target 5 × 105;
maximum injection time 100ms). Precursors for MS2/MS3
analysis were selected using a Top10 method. MS2 analysis
consisted of collision-induced dissociation (quadrupole ion trap
analysis; AGC 2 × 104; normalized collision energy (NCE)
35; maximum injection time 200ms). Following acquisition
of each MS2 spectrum, we collected an MS3 spectrum using
our recently described method (23) in which multiple MS2
fragment ions were captured in the MS3 precursor population
using isolation waveforms with multiple frequency notches. MS3
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precursors were fragmented by high-energy collision-induced
dissociation (HCD) and analyzed using the Orbitrap (NCE 65;
AGC 2 × 105; maximum injection time 300ms, resolution was
50,000 fat 400 Th).
Data Analysis of MS-Data
Mass spectra were processed using a Sequest-based in-house
software pipeline (24), and spectra were converted to mzXML
using a modified version of ReAdW.exe. Database searching
included all entries from the human uniprot database (March 11,
2014). This database was concatenated with one composed of all
protein sequences in the reversed order. Searches were performed
using a 50 ppm precursor ion tolerance for total protein level
analysis. The product ion tolerance was set to 0.9 Da. These wide
mass tolerance windows were chosen to maximize sensitivity
in conjunction with Sequest searches and linear discriminant
analysis (24, 25). TMT tags on lysine residues and peptide N
termini (+229.163 Da) and carbamidomethylation of cysteine
residues (+57.021 Da) were set as static modifications, while
oxidation of methionine residues (+15.995 Da) was set as a
variable modification.
Peptide-spectrum matches (PSMs) were adjusted to a 1%
false discovery rate (FDR) (26, 27). PSM filtering was performed
using a linear discriminant analysis, as described previously
(24), while considering the following parameters: XCorr, 1Cn,
missed cleavages, peptide length, charge state, and precursor
mass accuracy. For TMT-based reporter ion quantitation, we
extracted the summed signal-to-noise (S/N) ratio for each TMT
channel and found the closest matching centroid to the expected
mass of the TMT reporter ion.
The search space for each reporter ion was limited to a range
of 0.003 Th to prevent overlap between the isobaric reporter ions.
For protein-level comparisons, PSMs were identified, quantified,
and collapsed to a 1% peptide false discovery rate (FDR) and then
collapsed further to a final protein-level FDR of 1%. Moreover,
protein assembly was guided by principles of parsimony to
produce the smallest set of proteins necessary to account for all
observed peptides.
Proteins were quantified by summing reporter ion counts
across all matching PSMs using in-house software, as described
previously (24). PSMs with poor quality, MS3 spectra with more
than eight TMT reporter ion channels missing, MS3 spectra
with TMT reporter summed signal-to-noise ratio that is less
than 100, or no MS3 spectra were excluded from quantitation
(28). Protein quantitation values were exported for further
analysis in Microsoft Excel and GraphPad Prism (version 8).
The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE (http://
www.proteomexchange.org) partner repository with the dataset
identifier PXD012081.
PC-plots were generated with default settings using the
web based tool ClustVis (29). The pathway analyses were
generated through the use of QIAGEN’s Ingenuity Pathway
Analysis (IPA R©, QIAGEN Redwood City, www.qiagen.com/
ingenuity). Briefly, the analyses were performed with the
following settings: Expression Value Type (Exp Log Ration),
Reference set (Ingenuity Knowledge Base + Endogenous
chemicals), Relationships to consider (Direct and Indirect
Relationships), Interaction networks (70 molecules/network;
25 networks/analysis), Data Source (all), Confidence
(Experimentally Observed), Species (Human, Mouse, Rat),
Tissue & Cell Lines (all), Mutations (all).
Statistics
R was used to normalize the data based on the common and
homogenized adult human islet samples that were similar in
each TMT11-plex run. Adult human islets (n = 2) in each
TMT 11 plex experiment, in total n = 6 islet samples were
analyzed. The normalized data was log2 transformed. As all
samples were normalized to islets, the abundance of each protein
from the islets will be equal to 1. R was also used for Euclidean
distance measure on log2 scale between the different conditions
and mean of islets. Two-sided unpaired t-test was performed
GraphPad Prism (version 8), when specified. Results were
expressed as mean with SEM and three data points were given
corresponding to biological triplicates in each case the protein
abundance were detected in all data sets. Statistical significance
was considered p < 0.05.
RESULTS
To investigate the role of Wnt modulation in hiPSC-derived
S7 cells, three lines of hiPSCs, derived from three different
human healthy subjects, generated through three different
reprogramming methods, were differentiated using an
established 7-stage differentiation protocol to produce S6
and S7 cells (corresponding to immature and maturing β-like
cells, respectively) (1). S7 cell populations were maintained for
7 and 14 days, (here on S7d7 and S7d14 cells), respectively. S7
cells were treated with the selected Wnts and TKi for 4 h, and
maintained in culture for an additional 48h before assessing the
effect of Wnt-modulation on in vitro maturation. As negative
and positive controls, respectively, we used un-stimulated S7
cells and adult human islets (Figure 1).
Wnt-Modulation Did Not Compromise Cell
Viability of hiPSC-Derived S7 Cells
For modulating Wnt-signaling in hiPSC-derived S7 cells, we
chose to use similar concentrations as previously used for the
WNT-ligands to stimulate Wnt-signaling in murine micro islets,
human islets, as well as human β-cell line EndoC-BH1 (7). To
ensure that Wnt-modulation did not induce apoptosis in our
hiPSC-derived S7 cells, we assessed cell viability every 15min by
Annexin V and Propidium Iodide staining. Following the 4-h
incubation, regardless of Wnt modulation, the S7 cells showed
no membrane staining by Annexin V or nuclear staining for
Propidium Iodide (data not shown).
To check for delayed reduction in viability, the viability
of S7 cells was also checked at the moment of collection,
i.e., 48 h after the Wnt-modulation (Supplementary Table 1).
The overall viability of control untreated S7 cells was 89%.
The WNT5B treated cells displayed an inversely correlated
dose-dependent viability from 60% at 400 ng/mL to 71% at
80 ng/mL. In contrast, the viability of the S7 cells increased
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FIGURE 1 | Experimental design. (A) With this experimental set-up we aimed to assess whether Wnt-modulation could drive maturation of S7 cells toward a
phenotype that closer resembles that of β-cells as found in adult human islets. To assess the effects of Wnt-modulation of S7 cells, the Wnt-modulated cells were
compared to un-stimulated S7 cells as well as to adult human islets. (B) S7d7 cell cultures were treated for 4 h with either WNT3A (light green), WNT4 (green), WNT5A
(orange), WNT5B (red), a combination of WNT5A&5B (dark red) for stimulation of the canonical or non-canonical Wnt pathways, or TKi (yellow) to block endogenous
Wnt signaling in S7d7 cell cultures. The Wnt-modulated S7 cells were maintained in differentiation culture for 48 h prior to harvest for downstream analysis [including
proteomics analysis and immunofluorescence (IF)].
with the concentration of TKi from 53% at 1 µmol/L
to 73%, respectively at 5 µmol/L. We chose to treat S7
cells with WNT3A (200 ng/mL), WNT4 (100 ng/mL), WNT5A
(400 ng/mL), WNT5B (80 ng/mL), WNT5A&5B combination
(400/80 ng/mL) and TKi at a concentration of 5 µmol/L. Overall,
these results show that modulating the Wnt pathways in S7 cells
for 4 h does not compromise cell viability, and causes only mild
decrease in viability at later stages.
Wnt Modulations of S7-Cells Show
Heterogeneous Expression of Downstream
Targets 48h After Treatment
As we were aiming to assess whether Wnt-modulation could
affect the in vitro maturation of hiPSC-derived insulin-
producing cells, we did not harvest cells directly following the
respective Wnt-treatments, but instead maintained the cells in
S7 differentiation conditions for 48 h to promote maturation.
First, we examined if the direct effect of Wnt-modulation
persisted 48 h after treatment, by immunofluorescence (IF) and
assessing the abundance of relevant proteins from our global
proteomics analysis.
The canonical Wnt-ligand, Wnt3A, acts on target cells by
binding to the frizzled receptors and LPR5/6 co-receptors, and
induce accumulation of the un-phosphorylated form of β-catenin
in the cytoplasm, making it available for entry into the nucleus,
where the protein stimulates transcription of Wnt target genes
(30) (brief overview of Wnt signaling pathways Figure 2A,
interaction partners of the selected Wnt-ligands Figure 2B). In
contrast, other Wnt ligands, such as Wnt4, Wnt5A and Wnt5B
can activate non-canonical signaling cascades, such asWnt/Ca2+
and PCP pathways (31) (Figure 2A).
IF revealed that most un-stimulated S7 cells were
low BMP4 expressers with just small pockets of elevated
expression. In contrast, both WNT3A and WNT4 stimulated
cells show an increased BMP4 expression in the nucleus
(Figure 2C). Dependent on receptor context [alternative
Wnt-receptor ROR2, FZ4 or LRP5(32)], WNT5A can activate
or inhibit Wnt signaling. It has been shown that in the
presence of ROR2, WNT5A inhibits β-catenin signaling in
a GSK3β-independent manner (33). Here our IF showed
regions of ROR2 expression in the plasma membrane of
WNT5A-stimulated S7 cells (Figure 2C). Furthermore,
WNT5B can activate Wnt/β-catenin, Wnt/Ca2+ and
PCP pathways, and regulates β-catenin and JNK. IF of
WNT5B-treated S7 cells showed pockets of nuclear c-JUN
expression (Figure 2C).
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FIGURE 2 | S7-cells show heterogeneous expression of downstream targets 48 h after Wnt-modulator treatment. (A) Schematic overview of key proteins of the
canonical and non-canonical Wnt signaling pathways, in brief, Wnt ligand binds to its receptor Frizzled and co-receptors LRP5/6, receptor tyrosine kinase, (or ROR2)
and transmits the signal via disheveled (Dvl) into the cytoplasm to activate the canonical Wnt pathway, or functions through non-canonical planar cell polarity (PCP)
and Wnt/Ca2+. In the canonical Wnt signaling pathway, β-catenin accumulates in the cytoplasm and translocate to the nucleus to act as a transcription coactivator
for the TCF/LEF transcription factor family. Without Wnt, β-catenin is degraded by the destruction complex, composed of Axin, adenomatosis polyposis coli (APC),
glycogen synthase kinase 3β (GSK3β) and casein kinase 1α (CK1α). The non-canonical Wnt/PCP pathway is thought to use Ryk or ROR2 for activation; Dvl is
recruited to form a complex with disheveled-associated activator of morphogenesis 1 (DAAM1). DAAM1 activates Rho that again activates Rho-associated kinase
(ROCK). Dvl can also form a complex with Rac1 to activate JNK via the MAPK pathway. In the Wnt/Ca2+ pathway, binding of Wnt to Frizzled activates a trimetic
G-protein leading to activation of PLC to cleave PIP2 to form DAG and IP3. IP3 binds to its receptor on the endoplasmic reticulum and calcium is released. Increased
concentrations of calcium and DAG can again activate PKC and CaMKII. (B) A selection of interaction partners of the selected Wnt-ligands (30–33). (C) IF of
β-catenin, BMP4, ROR2 and c-JUN in S7 cells, WNT3A, WNT4, WNT5A, WNT5B treated S7 cells, respectively. Scale bar 50µm.
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Independent ofWnt-modulation, IF revealed a heterogeneous
expression of β-catenin in the membrane and the cytoplasm
of the stimulated S7 cells (Figure 2C; in green) suggesting
that the time point of β-catenin translocation was passed 48 h
after Wnt-treatment, further suggesting that direct response
to the relevant Wnt-ligands occurred prior to our time point
of harvest of S7 cells. Wnt-downstream target proteins were
also heterogeneously expressed among the S7 cell population
(Figure 2C). An explanation for this mosaic pattern is the already
known high heterogeneity of the S7 cell population itself (6). Due
to this intra-sample variation, our bulk proteomic assay could
potentially not detect significant differences in these specific
protein abundances between different S7 samples.
Of note, previous findings show that WNT4 induced JNK
activation in the EndoC-β H1 cell line (7). These findings,
however, fail to compare this increased expression with its natural
expression in human islets or isolated β-cells. Interestingly,
our proteomics data revealed that untreated S7 cells already
exhibit higher JNK levels as compared to adult human islets,
suggesting that any further up-regulation by WNT4 treatment
will push these cells even further away from their β-likemolecular
fingerprint goal (Supplementary Figure 1A). A similar example
is JUN, displaying similar levels between un-stimulated S7
cells and islets, which upon Wnt-treatment were reduced
(Supplementary Figure 1A).
Taken together these results show that very few direct markers
of Wnt-pathway modulations persisted 48h after the treatment.
However, our aim of this study was to assess the influence of
Wnt-modulation on in vitromaturation of S7 cells.
Wnt-Modulation Influences the
Heterogeneity of the S7 Cell Population
The islets of Langerhans contain five different endocrine
cell types such as glucagon-secreting α-cells, insulin-secreting
β-cells, somatostatin-secreting δ-cells, pancreatic polypeptide-
secreting PP-cells and ghrelin-secreting ε-cells. Differentiation
of hiPSCs to achieve mono-hormonal β-like cells that display
controlled glucose-responsiveness has been proven to be difficult
to achieve (4). As reported previously (6), we have also
experienced that S7 cells display a high and unavoidable
degree of heterogeneity with few mono-hormonal insulin+ cells,
and many bi-hormonal insulin+/ glucagon+ cells, as well as
mixtures of the transcription factors Pancreatic and duodenal
homeobox 1 (PDX1) and homeobox protein NKX6.1, i.e.,
NKX6.1+/PDX1+, NKX6.1+/PDX1– and NKX6.1–/PDX1+
cells (Figures 3A, D). By comparing S6 cells corresponding to
immature β-like cells (1) to S7 cells, we found as expected
that the level of bi-hormonal cells decreased during in vitro
maturation of hiPSC-derived cells (Figure 3C). Following Wnt-
modulations, TKi induced the expression of islet-like groups
of insulin+ cells, and displayed the significantly highest
fraction of insulin+ cells and significantly lowest fraction
of bi-hormonal cells to mono-hormonal cells as compared
to the other Wnt-modulators (Figures 3A–C) and to un-
stimulated S7 cells. In contrast, WNT3A treated S7 cells
displayed the highest fraction of bi-hormonal cells and the
lowest numbers of insulin-only expressing cells (Figures 3B,C,
Supplementary Figure 2). Interestingly, most of the glucagon+
cells (95%) in the WNT3A-treated S7 cells were bi-hormonal,
in which few single-hormonal glucagon+ cells were found
(Figure 3C). WNT4 treated S7 cells included many individually
located mono-hormonal insulin+ cells, but a higher fraction
of bi-hormonal cells compared to TKi-stimulated cells. The
combined stimulation of WNT5A&5B increased the number
of both mono-hormonal insulin+, mono-hormonal glucagon+
cells (Figure 3B), as well as the fraction of bi-hormonal cells
as compared to un-stimulated cells. We also checked IF
of PDX1 and NKX6.1, but did not detect WNT-dependent
alterations in PDX1/NKX6.1 expression, although we noted that
Wnt-modulation led to extensive heterogeneity with mixtures
of NKX6.1+/PDX1+, NKX6.1+/PDX1– and NKX6.1–/PDX1+
cells (Figure 3D).
Wnt-Modulation of S7 Cells Leads to
Altered Levels of Pancreatic
Endocrine Proteins
We next investigated the effects of Wnt-modulation of S7 cells
on protein level based on quantitative proteomics assessment
(Figure 4A). First, we assessed the abundance of pan-endocrine
markers Synaptophysin (SYP) and Chromogranin A (CHGA)
(Figure 4B). For SYP we observed increased levels after Wnt-
modulation, both after Wnt-stimulation and -inhibition (TKi).
Whereas some Wnt-treatments yielded SYP levels close to the
islet levels, other Wnt-treatments led to even higher levels than
islet levels. CHGA levels were not significantly altered, suggesting
that modulating the Wnt pathway has no effect on its regulation.
Further, we grouped the selected markers according to their
role in β-cell function, with groups of islet hormones, of
typical mature β-cell transcription factors, ion channels, proteins
involved in the regulation of glucose-stimulated insulin secretion
(GSIS), and of proteins involved in granulogenesis (PC-plots and
relative abundance charts Figure 4C, respectively). As expected,
the levels of pancreatic hormones (INS, GLU and SST) were
lower than in adult human islets, and none of the selected Wnt-
modulation led to islet hormone levels closer to that of human
islets (Figure 4C).
The transcription factors PDX1, NKX6.1 and pancreatic β-
cell-specific transcriptional activator MAFA are markers of adult
human β-cells (34), together with insulin gene enhancer protein
ISL1. Wnt-modulation had a moderate effect on the expression
β-cell transcription factors (PDX1, NKX6.1, MAFA, and ISL1),
which exhibited intermediate PC1 values between islets and un-
stimulated S7 control cells (Figure 4C). WNT4 has previously
been reported to increase the levels of NKX6.1 and PDX1 protein
in the human EndoC-βH1 β-cell line, and human islets (7). Based
on our proteomics data, the protein levels of NKX6.1, PDX1,
and MAFA showed an opposite pattern with higher levels in
both S6 and S7 cells as compared to adult human islets (protein
plots in Figure 4C). Wnt-modulation of S7 cells seemed to
reduce the protein level of PDX1 and MAFA, while NKX6.1 was
increased by WNT3A, WNT4, WNT5B, and the WNT5A&5B
combination. Whereas TKi did not change the NKX6.1 protein
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FIGURE 3 | Wnt-modulation influences the distribution of mono-hormonal and bi-hormonal S7 cells. (A) Representative schematic drawing and IF analysis for
insulin+ (red), glucagon+ (green) cells and insulin+/glucagon+ cells (yellow) of the respective S7 cell populations. (B) Calculations of insulin+ (red, left) and
glucagon+ (green, right) cells were done as described in Methods. The y-axis shows the number of insulin+ and glucagon+ cells, respectively. The figure shows
standard error of the mean (SEM) values for each of the columns in bar charts. **P < 0.006, ****P < 0.0001 vs. S7 cells with two-tailed t-test. No significant
comparisons show no stars. The number of insulin+ cells and glucagon+ cells were normalized to total cell count (dapi+ cells) see Supplementary Figure 2.
(C) Overlay of insulin+ and glucagon+ were used to count bi-hormonal cells, in which bi-hormonal (ins+glu+) cells were calculated as a fraction of insulin+ (red bar
chart) and glucagon+ (green bar chart) cells, respectively. The figure shows standard error of the mean (SEM) values for each of the columns in bar charts.
**P < 0.006, ****P < 0.0001 vs. S7 cells with two-tailed, type two t-test. No significant comparisons show no stars. (D) IF analysis of NKX6.1+ (red), PDX1+ (green)
cells and NKX6.1+/PDX1+ cells (yellow). Scale bar upper panel: 25µm, lower panel: 7.5µm.
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FIGURE 4 | Pancreatic endocrine markers. (A) Schematic drawing of the color code for the different samples analyzed. (B) Protein abundance of pan-endocrine
markers Synaptophysin (SYP) and Chromogranin (CHGA) in S6, S7d7, S7d14, Wnt-modualted S7 cells and adult human islets. The y-axis shows normalized fold
change vs. islets for each protein. The data shown is normalized protein levels from all cell lines (n = 3, when detected) and is shown as mean with SEM. (C) PC-plots
for hormones (INS, GCG, SST), transcription factors (PDX1, NKX6.1, MAFA, and ISL1), ion channels (ABCC8, KCNK1), GSIS regulators (GCK, PCSK1, PCSK2,
LDHA, HK1, HK2, ALDOB) and proteins involved in granulogenesis (CHGA, CHGB, PTPRN, PTPRN2). Unit variance scaling is applied to rows. Singular value
decomposition(SVD) with imputation is used to calculate principal components. X and y-axis show principal component 1 and principal component 2 that explain the
% of the total variance, respectively. N = 8 data points. Also included are charts showing normalized fold change (y-axis) for each protein vs. islets. The data shown is
normalized protein levels from all cell lines (n = 3, when detected) and is shown as mean with SEM. *P < 0.05, **P < 0.006 as vs. islets (normalized abundance level
of adult human islets as reference) t-test. No significant comparisons show no stars.
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FIGURE 5 | Proteome changes in response to Wnt-modulation of S7 cells.
(A) Euclidean distance on log2 scale between S7 cells and the different
Wnt-modulated S7 cell conditions and adult human islets. Of the three cell
lines (n = 3, biological triplicates), TKi had the lowest distance measured
between TKi-treated S7 cells vs. adult human islets. (B) Using quantitative
proteomics data from one of the cell lines we examined the global proteome
effect of endogenous Wnt inhibition by TKi on S7 cells resulting in increased
abundance of 755 proteins (FC > 2) and decreased abundance of 177
proteins (FC < −2). The IPA software predicted upstream regulators protein
signature based on these differentially regulated proteins.
levels as compared to S7 cells. The protein abundance of ISL1 was
minimally affected by Wnt-treatment.
To further characterize our S7 cells response to the different
Wnt-modulations we assessed the various components of the
glucose sensing machinery. We found no clear effects by Wnt-
perturbations on the protein levels of ion channels (ABCC8
(SUR1) and KCNK1) (Figure 4C) or the levels of glycolytic
enzymes (GCK, PCSK1, PCSK2, HK1, HK2, LDHA, ALDOB)
(PC-plot and protein plots in Figure 4C; protein plots for
HK1, HK2, LDHA, ALDOB in Supplementary Figure 1A)
or proteins involved in granulogenesis (CHGA (Figure 4B),
CHGB, PTPRN, PTPRN2). Moreover, to test the effect of
Wnt-modulation on the functionality of the S7 cells we
performed a static glucose-stimulated insulin secretion assay.
This showed that neither of the WNT modulators improved
or altered glucose stimulated insulin secretion of S7 cells
(Supplementary Figure 1B), and fold difference in insulin
secretion (Supplementary Figure 1C). In short, these results
suggest that Wnt-treatment did not change the levels of
essential proteins involved in the fine-tuned regulation of
insulin secretion, although the grouped transcription protein
levels displayed a tendency toward the protein levels of
human islets.
Inhibition of Endogenous Wnt Signaling by
TKi Brings S7 Cellular Proteome Closer to
That of Adult Human Islets
Although assessment of specific β-cell proteins did not alter with
Wnt-modulation toward the levels in human islets, we aimed to
assess if there were anyWnt-modulating effects driving the global
proteome of S7 cells toward an adult human islet-fate. To assess
this, we compared all protein abundances of the adult human islet
proteome (n = 9,602 proteins) to that of S7 cells stimulated with
the selected Wnt-ligands (WNT3A, WNT4, WNT5A, WNT5B,
and WNT5A&5B) or TKi. We calculated the Euclidean distance
on log2 scale between S7 cells, each Wnt-modulated S7 cells
and adult human islets. Inhibition of endogenous Wnt signaling
by TKi had the lowest distance measured as compared to adult
human islets for the three cell lines (Figure 5A).
To evaluate the effect of inhibiting endogenous Wnt signaling
by TKi in S7 cells, we first assessed the activation status of
the Wnt/β-catenin, Wnt/Ca2+ and Wnt/PCP pathways using
the IPA software. IPA predicted negative activation z-scores
for Wnt/β-catenin, Wnt/Ca2+ and Wnt/PCP pathways in TKi-
treated S7 cells compared to untreated S7 cells, suggesting
inhibited pathway activity in S7 cells as an effect of Tankyrase
inhibition (Supplementary Table 2).
To further assess the global proteome effect of TKi inhibition
of S7 cells, we compared the proteome of TKi-treated S7
cells to the proteome of S7 cells from one of the cell lines,
resulted in increased abundance of 772 proteins (FC > 2) and
decreased abundance of 174 proteins (FC < −2). To investigate
the biological significance of these proteins, we used the IPA
software. Based on the protein abundance profiles [946 proteins
(2< FC<−2)], IPA predicted a signature of upstream regulators
for TK inhibition of S7 cells (Figure 5B). Among the predicted
activated upstream regulators, we found HNF4A, STAT1, AKT1,
DNMT3A, HNF1A, and FOXO1. CST5 and SIRT1, a regulator of
TP53 and FOXO1 were among the upstream regulators predicted
as inhibited.
Frontiers in Endocrinology | www.frontiersin.org 10 May 2019 | Volume 10 | Article 293
Vethe et al. hiPSC-Derived Pancreatic Beta Cell Maturation
DISCUSSION
In this study, we are the first to report a comprehensive
characterization study of the effects of Wnt-modulation on
in vitro maturation of hiPSC-derived S7 cells toward the profile
of adult human islets.We found thatWnt-inhibition significantly
increased the fraction of mono-hormonal S7 cells and reduced
the fraction of bi-hormonal cells, whereas Wnt-stimulation
did not affect these ratios. Wnt-inhibition also increased the
similarity of the global proteomic signature of S7 cells and human
islets, whereas singular proteomics-based maturation markers
and glucose-stimulated insulin secretion were unchanged.
Previous studies investigating Wnt signaling in β-cells (7, 13,
16) have used variable time windows for the perturbation of
Wnt signaling, ranging from 4 h to 4 days. Also the maintenance
in culture following Wnt-modulation has varied. Nostro et al.
stimulated pancreatic endoderm cell populations with WNT3A
and the Wnt inhibitor for 3 days (17), following culture in
four additional days to promote maturation, in which WNT3A
increased INS expression. Bader et al. stimulated micro islets and
human islets for 4 days with WNT4, and the human β-cell line
EndoC-BH1 for 4 h and 4 days (7), in which WNT4 increased
the expression of PDX1 and NKX6.1 in the EndoC-BH1 cells as
well as human islets. However, none of these studies reported
apoptosis monitoring which could potentially bias the results.
In our studies of Wnt-perturbation of S7 cells, we observed no
induction of apoptosis occurring before 4 h, nor at the moment
of collection.
In the pancreas, Wnt signaling has several important roles in
pancreatic development and islet functions (16), and previous
studies have focused on the role of Wnt signaling in β-cells
(7, 13, 16). Stage-specific signaling through Wnt regulates
patterning and pancreas specification of hPSCs, and canonical
Wnt signaling has been found to promote the development of
pancreatic linage cells (17). We recently reported strong Wnt
activation to be characteristic of immature hiPSC-derived S7
cells when compared to adult human islets (18). Our previous
findings are in agreement with Qiu et al., in which single-cell
RNA-seq analyses of mouse β-cell from fetal to adult stage of
development, identified enrichment of Wnt signaling pathways
in immature compared to mature β-cells (35). In contrast to
P5 murine islet cells, Min6 cells and the adult human β-
cell line EndoC-BH1(7), we found that modulation of non-
canonical Wnt signaling did not improve GSIS of S7 cells.
Contradicting previous findings of WNT4 increasing levels of
NKX6.1 and PDX1 protein in the human EndoC-β H1 β-
cell line (7), we found that WNT4 reduced the protein levels
of PDX1and MAFA as compared to un-stimulated S7 cells.
However, WNT4 affected the protein levels of these β-cell
transcription factors to become more similar to the protein
levels of adult human islets. Surprisingly, NKX6.1 and MAFA
levels were lower in human islets (positive control) compared
to un-stimulated S7 cells (negative control). We believe this
is caused by the islet being a mixture of several different cell
types diluting the signals of the low-abundant transcription
factors. A previous report indicated that WNT3A stimulation
(and not DKK1 stimulation) induced INS expression but not
PDX1 expression (17). We, however, report unaltered INS
and PDX1-expression.
To test our hypothesis that inhibition of endogenous Wnt
signaling promotes β-cell-like maturation of S7 cells, we used
the small molecule Tankyrase inhibitor to block endogenous
Wnt signaling in S7 cell cultures. TKi acts inhibitory by
promoting formation of membrane-free structures containing
active components of the WNT/β-catenin destruction complex
in colorectal cancer cell lines (36). TKi has been reported
to decrease Wnt signaling in colon carcinoma cells (37), but
the effect of tankyrase inhibition of hiPSC-derived S7 cells
has to our knowledge never been investigated. We found that
TKi-treated S7 cells increased the fraction of insulin+ cells
significantly, and at the same time reduced the fraction of
bi-hormonal cells significantly as compared to untreated S7
cells. Moreover, the global proteome signature of TKi-treated
S7 cells was more similar to that of adult human islets, as
compared to stimulatory Wnt-modulations and un-treated S7
cells. Finally, activation scores for Wnt/β-catenin, Wnt/Ca2+
and Wnt/PCP pathways indicated that all these pathways were
inhibited by TKi. Taken together, these findings suggest that
inhibition of both endogenous canonical and non-canonical
Wnt-signaling pathways via tankyrase inhibition may promote
maturation of S7 cells. However, using various TK inhibitors
(i.e., G-631, XAV939, JW55) (36) or other Wnt inhibitors (i.e.,
DKK) (17) with differences in their specificities (i.e., affecting
either canonical or non-canonical signaling) would probably
even better define to which degree each of the canonical
or non-canonical signaling pathways contributes to beta cell
maturation, and whether selective inhibition would exert an
even larger effect. In addition, we assessed a heterogenous
pool of unsorted S7 cells potentially diluting an underlying
larger effect on maturation. Sorting beta cells (38, 39) would
probably enrich the population of studied S7 cells to yield
potentially maturation effects of a greater magnitude, but our
lines lacked sortable reporters analogous to the Mel1 Ins-GFP
reporter lines used by others (40), and there are to our knowledge
no sorting procedures established for stem-cell derived S7
cells. Further analysis of upstream regulators predicting the
molecular proteomic signature overlapping proteins of TKi-
modulated S7 cells and human islets indicated several proteins
with relevance for β-cell maturation, most notably DNA
methyltransferase (DNMT3A). DNMT3A plays a key role in
β-cells maturation after birth, in which the protein represses
Ldha, Hk1, and AldoB, and thereby enable the coupling of
insulin secretion to glucose levels, which results in GSIS (41). β-
cell repression of these key metabolic genes is essential toward
maintenance of a functional mature phenotype. Our results
suggest that TKi modulation of S7 cells changed the proteome
comparable to what would have been observed by activation
of DNMT3A.
The inherent relative low efficiency of targeted differentiation
and striking heterogeneity of cells using current protocols
combined with extensive cell line variability clearly limits
reproducible analysis of maturity and functionality of β-like
cells derived from hiPSC and hESCs. Although there are clear
advances in protocols for generating hPSC-derived β-like cells
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with a partly functional and mature phenotype (1–3), these
published sequences have been optimized for specific hESC lines
and lacks optimization for other stem cell lines, in particular
for hiPSCs.
As we have reported previously (18), direct comparison of
the proteome of S7 cells to adult human islets, is required
to characterize β-cell maturity as an addition to evaluating
existing markers and functional assays. As reported previously
by Nostro et al, endogenous BMP signaling varies substantially
between different hESC lines and can dramatically affect the
outcome of the pancreatic differentiation protocol (17). In
this current study, we addressed variability by reporting the
results from analysis of three lines of hiPSCs, derived from
three different human healthy subjects, generated though three
different reprogramming procedures. The efficiency of the
differentiation varied between hiPSC lines, but also the response
to the different Wnt-modulations. As previously described (6),
S7 cells displayed a high and unavoidable degree of heterogeneity
with few mono-hormonal insulin+ cells, and many bi-hormonal
insulin+/ glucagon+ cells. The S7 cellular response to Wnt-
modulations also displayed heterogeneous expression of BMP4,
β-catenin, ROR2, c-JUN, PDX1, NKX6.1, as well as INS and
GCG.We believe that optimizing current targeted differentiation
protocols for a larger range of different stem cell lines, also
including hiPSCs, will substantially improve reproducibility and
allow for more robust studies of the role of specific pathways in
β-cell maturation.
In conclusion, we have comprehensively assessed the role of
Wnt-modulation in the final maturation stage of pancreatic β-
like cells using a current state-of-the art targeted differentiation
protocol. Our results indicate that Wnt-inhibition may modestly
improve β-cell maturation.
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Supplementary Figure 1 | (A) Protein levels of JNK and JUN in the
Wnt-modulated S7 cells detected by quantitative proteomics. The y-axis shows
normalized fold change vs. adult human islets. Data presented normalized protein
levels from all three cell line (n = 3) and is shown as mean with SEM. ∗P < 0.05,
vs. islets, with two-tailed, type two t-test. (B) Protein charts for proteins involved in
GSIS regulation (LDHA, HK1, HK2, ALDOB). (C) Insulin secretion of S7d7 cells
and Wnt-modulated S7 cells after static incubation in 1.67mM glucose (low
glucose) for 30min, 20mM glucose (high glucose) for 30min, and 20mM glucose
supplemented with 30mM KCl (high glucose + KCl) for 10min. The insulin levels
were normalized to the total cell number in each well for each condition. N = three
hiPSC-derived cell lines. The data is shown as mean with SEM. ∗ marks significant
GSIS as compared to S7 cells, no significant results were obtained.
Supplementary Figure 2 | Dapi+ cells were counted from three confocal areas
for each condition to calculate the % insulin+ and % glucagon + cells as
normalized to total number of dapi+ cells.
Supplementary Table 1 | The viability of S7 cells was also checked 48 h after
Wnt-treatment. We chose to treat S7 cells with WNT3A (200 ng/mL), WNT4
(100 ng/mL), WNT5A (400 ng/mL), WNT5B (80 ng/mL), WNT5A&5B combination
(400/ 80 ng/mL) and TKi at a concentration of 5 µmol/L). The table shows the
viability of S7 cells at each of the concentrations of Wnt-modulators tested.
Supplementary Table 2 | Activation status of Wnt/β-catenin, Wnt/Ca2+, and
Wnt/PCP pathways in TKi-treated S7 cells as compared to untreated S7 cells,
The significance values for the canonical pathways is calculated using Fisher’s
exact test and assuming a right-tailed distribution (-log(p-value)). The significance
indicates the probability of association of proteins from our dataset with proteins
of the canonical pathway by chance alone. Ratio denotes here the number of
proteins from our data set annotated as involved in the pathway as a fraction of all
proteins annotated in the given pathway. IPA predict activated pathways (positive
z-scores) or inhibited pathways (negative z-scores) based on the relative
abundance of all proteins annotated in Wnt pathways from our dataset.
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